Table 2. Hazard ratios (95% confidence intervals) for breast cancer-specific mortality within HR+, HER2- subtype, by Stage.
| Stage I NOS/IA | Stage IB | Stage IIA | Stage IIB | Stage III NOS/IIIA | Stage IIIB-C | |
|---|---|---|---|---|---|---|
| Hazard Ratio (95% CI) | ||||||
| Sex (reference, female) | ||||||
| Male | 2.03 (1.12, 3.69) |
0.82 (0.11, 5.99) |
0.96 (0.54, 1.70) |
1.46 (0.89, 2.39) |
1.20 (0.70, 2.04) |
0.59 (0.34, 1.02) |
| Age group (reference, 18–49) | ||||||
| 50–59 | 1.03 (0.77, 1.39) |
1.41 (0.73, 2.74) |
1.18 (0.96, 1.46) |
1.26 (1.05, 1.52) |
1.11 (0.92, 1.32) |
1.01 (0.85, 1.22) |
| 60–69 | 1.51 (1.16, 1.97) |
1.16 (0.59, 2.31) |
1.37 (1.12, 1.69) |
1.25 (1.03, 1.52) |
1.23 (1.02, 1.48) |
1.08 (0.90, 1.29) |
| 70–79 | 2.62 (2.02, 3.42) |
2.58 (1.29, 5.14) |
2.28 (1.85, 2.81) |
1.73 (1.41, 2.13) |
2.10 (1.73, 2.56) |
1.43 (1.18, 1.75) |
| 80–89 | 4.25 (3.16, 5.73) |
3.86 (1.75, 8.50) |
3.78 (3.00, 4.76) |
3.48 (2.78, 4.36) |
3.44a (2.75, 4.30) |
2.83a (2.31, 3.48) |
| 90+ | 6.87 (3.16, 14.92) |
N/A | 3.84 (1.96, 7.53) |
6.68 (4.25, 10.49) |
6.24 (4.02, 9.69) |
2.86 (1.76, 4.66) |
| Race/ethnicity (reference, non-Hispanic White) | ||||||
| Spanish-Hispanic-Latino | 1.08 (0.83, 1.41) |
0.87 (0.40, 1.93) |
1.17 (0.95, 1.44) |
1.12 (0.92, 1.36) |
1.22 (1.01, 1.47) |
1.06 (0.88, 1.28) |
| Non-Hispanic Black | 1.51 (1.19, 1.91) |
1.83 (1.00, 3.34) |
1.66 (1.38, 1.99) |
1.18 (0.97, 1.42) |
1.80 (1.52, 2.13) |
1.46 (1.23, 1.73) |
| Non-Hispanic American Indian/Alaska Native | 1.85 (0.88, 3.91) |
N/A | 1.77 (0.84, 3.73) |
0.64 (0.24, 1.72) |
1.52 (0.72, 3.20) |
0.86 (0.41, 1.81) |
| Non-Hispanic Asian or Pacific Islander | 0.52 (0.35, 0.76) |
0.73 (0.26, 2.01) |
0.61 (0.45, 0.83) |
0.57 (0.43, 0.77) |
0.96 (0.75, 1.23) |
0.66 (0.50, 0.87) |
| Nodal status (reference, node negative) b | ||||||
| Micrometastasis 1–3 positive ipsilateral axillary nodes | N/A | N/A | N/A | 1.68 (1.15, 2.47) |
N/A | 1.74 (0.80, 3.82) |
| Micrometastasis ≥4 positive ipsilateral axillary nodesc | N/A | 2.02 (0.49, 8.30) |
N/A | 5.19 (2.54, 10.58) |
3.38 (1.59, 7.20) |
1.92 (0.45, 8.18) |
| Node positive 1–3 positive ipsilateral axillary nodesd | N/A | N/A | 1.34 (0.96, 1.87) |
2.15 (1.52, 3.04) |
1.83 (1.17, 2.87) |
2.39 (1.62, 3.52) |
| Node positive ≥4 positive ipsilateral axillary nodesd | N/A | N/A | 1.80 (0.25, 13.12) |
6.27 (3.51, 11.21)e |
2.46 (1.57, 3.85) |
2.47 (1.70, 3.58) |
| Histologic grade (reference, Grade 1) | ||||||
| Grade 2 | 1.73 (1.43, 2.09) |
1.46 (0.83, 2.58) |
1.32 (1.08, 1.61) |
1.69 (1.31, 2.18) |
1.21 (0.97, 1.51) |
1.24 (0.98, 1.56) |
| Grade 3 | 4.72a (3.83, 5.83) |
4.10a (2.23, 7.53) |
3.56a (2.91, 4.36) |
4.25a (3.30, 5.47) |
2.77 (2.21, 3.47) |
2.78 (2.20, 3.51) |
| Tumor size (reference, <1 cm) f | ||||||
| ≥1 cm to <2 cm | 1.56 (1.30, 1.87) |
1.08 (0.60, 1.94) |
0.80 (0.58, 1.12) |
N/A | 0.84 (0.47, 1.51) |
1.22 (0.67, 2.23) |
| ≥2 cm to <3 cm | 2.63 (1.99, 3.48) |
1.12 (0.47, 2.69) |
0.93 (0.60, 1.43) |
N/A | 1.15 (0.65, 2.03) |
0.87 (0.48, 1.58) |
| ≥3 cm to <4 cm | N/A | N/A | 1.41 (0.88, 2.26) |
1.48 (1.26, 1.73) |
1.45 (0.82, 2.56) |
1.33 (0.74, 2.38) |
| ≥4 cm to <5 cm | N/A | N/A | 1.65 (1.01, 2.69) |
1.98 (1.65, 2.37) |
1.82 (1.02, 3.23) |
1.42 (0.79, 2.56) |
| ≥5 cm | N/A | N/A | 1.40 (0.71, 2.76) |
2.64 (1.95, 3.58) |
2.05 (1.17, 3.59) |
1.80 (1.01, 3.19) |
| Histology (reference, infiltrating duct/lobular mixed) | ||||||
| Lobular carcinoma, NOS | 0.99 (0.67, 1.46) |
1.28 (0.43, 3.83) |
1.40 (1.03, 1.91) |
0.80 (0.59, 1.08) |
0.88 (0.69, 1.13) |
1,27 (1.00, 1.60) |
| Otherg | 1.26 (0.96, 1.66) |
1.27 (0.58, 2.78) |
1.49 (1.17, 1.91) |
1.22 (0.98, 1.53) |
1.00 (0.82, 1.23) |
1.05 (0.85, 1.28) |
aIndicates highest chi-square value within each Stage.
bReference group for Stage IB and Stage III NOS/IIIA is “Micrometastasis 1–3 Ips Ax nodes+”.
cPer the American Joint Committee on Cancer Staging Manual, micrometastases were defined as tumor deposits larger than 0.2 mm but not larger than 2.0 mm in the largest dimension. Cases in which at least 1 micrometastasis is detected, but no metastases larger than 2 mm are detected, regardless of number involved are classified as pN1mi or pN1mi(sn).
dIn these analyses, node positive was exclusive of the N1mi subgroups. Please refer to Materials and Methods section, Data Source subsection for detailed information regarding nodal status classification.
eIt is unclear if patients with Stage IIB tumors and with ≥4 positive ipsilateral axillary nodes were staged clinically, staged by proposed prognostic staging criteria (AJCC 8th Edition), or were staged incorrectly.
fReference group for Stage IIB is “Size ≥2 cm to <3 cm”.
gOther combines other adenocarcinomas, mucinous adenocarcinoma, and histologic subtypes with <1% of patients which included: phyllodes tumor, Paget disease, inflammatory adenocarcinoma, medullary adenocarcinoma, mucin-producing adenocarcinoma, tubular adenocarcinoma, adenocarcinoma not otherwise specified, epidermoid carcinoma, papillary adenocarcinoma, unspecified carcinoma, other specific carcinoma, unspecified, and other specific types.
Abbreviations: CI, confidence interval; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mi, microinvasive carcinoma; N1, node status; N/A, not applicable; NOS, not otherwise specified.